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ABSTRACT
ILYSE MIRIAM LEVY: THE EFFICACY OF THE COVID-19 VACCINE IN MISSISSIPPI
(Under the direction of Dr. Xin Dang)

By tracking and analyzing fifty-three weeks of COVID-19 data, this thesis analyzes the
efficacy of the COVID-19 vaccine within the State of Mississippi. Over the course of these fiftythree weeks, I have also been able to calculate the confidence intervals for vaccination efficacy
and the risk reduction due to vaccination by using data regarding the correlations between deaths
and vaccination status, provided to me by the Mississippi Office of Epidemiology. My analysis
demonstrates that the COVID-19 vaccine is effective not only in Mississippi but also across the
globe.
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PREFACE
This project has been my greatest accomplishment to date. I look forward to seeing the
impact that this thesis may have in the future.
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“Facts are stubborn things; and whatever may be our wishes, our inclinations, or the dictates of
our passion, they cannot alter the state of facts and evidence”.
-

John Adams

Introduction
In December of 2019, the COVID-19 virus made its first appearance in Wuhan, China.
Approximately one month after, in late January 2020, COVID-19 entered the United States. The
COVID-19 virus rapidly began infecting large numbers of people across the United States as
well as across the rest of the world. On March 11, 2020, the World Health Organization
(“WHO”) deemed this virus a pandemic, thus aligning it with previous detrimental pandemics,
such as the 2009 H1N1 Influenza and the 1918 Spanish Influenza. Just one day after the WHO
categorized this virus as a serious pandemic, COVID-19 emerged in the state of Mississippi on
March 12, 2020.

The rapid spread of this virus took the world by surprise, creating shortages of hospital
beds, personal protective gear, and morgues. This virus and its severity soon became life-altering
for people all around the world, which put pressure on companies to quickly create an effective
vaccine against the virus. Most vaccines contain a weakened or inactivated virus, which requires
adequate time to properly perform safety testing. Inactivated vaccines only induce antibody
mediated immunity. Subunit vaccines, on the other hand, only contain a portion of the virus,
usually a spike protein. Subunit vaccines cannot cause diseases; however, they may be less
1

effective because the immune system will not see the vaccine as a threat. Thus, this requires
some aggivents to be added to stimulate the antigen producing cells to pick up the vaccine. Since
vaccines containing inactivated viruses require extensive safety testing and subunit vaccines are
less effective, scientists and companies were pushed by the COVID-19 outbreak to find a
different, more effective vaccine form that could be produced and distributed quickly in attempt
to curb the pandemic. This need for a new vaccine led to the creation and distribution of three
COVID-19 vaccines: Moderna, Pfizer, and Johnson & Johnson.

Both Moderna and Pfizer are messenger RNA (“mRNA”) vaccines, which trigger an
immune response within the body by guiding human cells to make protein. The virus attaches
itself to human cells using its spikes. Messenger RNA vaccines introduce mRNA that contain
information for making the viral protein. These molecules are delivered in a lipid covering that
eventually fuse with the cell membrane. Then, inside the cytoplasm, the mRNA is translated into
viral antigen, which is then displayed on the surface of the cell. Although this form of vaccine is
more fragile and must be stored in a cold place, mRNA vaccines are extremely unlikely to
integrate into the human genome, which is not the case with DNA vaccines.

DNA vaccines, which help combat viruses within both animals and humans, introduce
viral DNA into the nucleus of the cell, where it is transcribed into mRNA, which is then
translated into viral spike protein in the cytoplasm and displayed on the cell’s surface. These
vaccines require a special delivery method to reach the nucleus of the cell, such as utilizing a
harmless unrelated adenovirus as a vehicle to deliver the DNA. This means the vaccine is also
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known as a viral vector vaccine. The viral vector vaccine cannot replicate or cause disease, but it
can deliver the DNA. However, the chosen viral vector cannot include anything that someone is
already immune to because it will blunt the effectiveness of the vaccine, so a non-human
adenovirus is chosen instead. DNA vaccines have raised concerns about the possibility of viral
DNA integration into the human genome; however, animal models have shown that integration
frequency is well below the frequency of natural spontaneous gene mutations.

Ultimately, mRNA vaccines were more effective with respect to COVID-19 because they
release viral antigens to trigger immune response without actually causing the disease. This type
of vaccine introduces mRNA that contains information for making the viral protein. These
molecules are delivered in a lipid covering that will eventually fuse with the cell membrane.
Then, inside the cytoplasm, the mRNA is translated into viral antigen, which is then displayed on
the surface of the cell. It then uses the host cell's machinery to replicate, which allows it to
produce more viral proteins and genetic material. This genetic material and viral protein release
more viral material that go on to infect more cells. These newly infected cells produce
symptoms. Infected cells alert the immune system by displaying viral proteins on their surface.
This presents the viral antigen to immune cells, such as Cytotoxic T-cells. The debris of dead
viral cells are picked up by antigen presenting cells, of which dendritic cells are most effective.
Dendritic cells (“APC”) patrol body tissues and sample their environment for intruders. The cells
then grab the antigen and go towards the nearest lymph node where they give the antigen to the
Helper T-cells, while also helping activate B- cells in lymph nodes.
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Although the process takes a few weeks after receiving the mRNA vaccine, the immune
cells created from the vaccine work together to form two types of immunity: cell mediated
immunity and antibody mediated immunity. The immunity process in response to a vaccine can
be similar to that of a mild infection, even though there is none. The lymph nodes can become
tender and swollen from antibodies forming in response to the vaccine; however, this is expected
because these are signs that the vaccine is working and preventing severe illness due to COVID19 [1].
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Section 1
Prior to gaining FDA approval for distribution of the COVID-19 vaccine, many case
studies had to be done to prove the overall safety and efficacy of the COVID-19 vaccines created
by different companies. The three companies that had successful case studies and were able to
eventually gain FDA approval are Pfizer, Moderna, and Johnson & Johnson.

In December 2020, Pfizer did a case study on the BNT162b2 mRNA COVID-19
Vaccine. This was done through a multinational, placebo-controlled, observer-blinded
randomized trial in which the vaccine was evaluated based on its efficacy and safety [2]. There
was a 1:1 randomization of patients 16 and older who were not immunocompromised to receive
two doses of either a placebo or the actual vaccine. These doses were given 21 days apart, and
each dose was tested on its safety side effects and overall efficacy against COVID-19. There
were a total of 43,548 participants that underwent randomization. Out of the 43,448 people that
received injections, 21,720 received the BNT162b2 (Pfizer) and the other 21,728 received the
placebo. Both population groups had very similar demographics, each containing around 50.5%
male, 49.5% female, and 57.7% of the participants were between 16 and 55 years old [2].

Ultimately, Pfizer’s case study revealed that the BNT162b2 vaccine was 95% effective in
preventing COVID-19. Throughout the trial, there were only 8 COVID-19 cases with BNT162b2
and 162 COVID-19 cases with the placebo. A two-dose regimen of BNT162b2 proved to
provide 95% protection against COVID-19 in persons 16 years of age or older. The safety of the
5

vaccine over a median of 2 months was comparable to that of other viral vaccines, such as side
effects including headache, nausea, and injection site soreness. The vaccine efficacy along with
the probability of approval were calculated by using the Bayesian beta-binomial model [2]. The
Bayesian beta-binomial model uses the underlying proportion of success as its only parameter,
making it easy to visualize in a trial similar to the Pfizer case study [3]. Thus, according to this
model, there was a “success boundary of 98.6% for probability of vaccine efficacy greater than
30% to compensate for the interim analysis and to control the overall type 1 error rate at 2.5%”
[2].

A few months later in February 2021, Johnson & Johnson was given FDA approval for
Emergency use of its single-dose COVID-19 vaccine for the prevention of COVID-19 in patients
18 years and older. This decision was made by the FDA due to the vaccine trial carried out by
J&J.

The Johnson & Johnson (“J&J”) single-dose COVID-19 vaccine trial was a Phase 3
ENSEMBLE study, which is a double-blind, placebo-controlled trial consisting of patients 18
years and older [4]. This case study analyzed the vaccine’s protection against moderate to severe
COVID-19 disease while also tracking its efficacy at the 14 day and 28-day mark after the
vaccine was administered. This trial was conducted across eight countries and three continents.
There was a total of 43,783 trial participants, with 14,672 participants 60 years or older. Out of
the total number of participants, 55% were male and 41% were immunocompromised or had
comorbidities.
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The trial showed that the J&J single-dose COVID-19 vaccine was 66% effective in
preventing moderate to severe COVID-19. The level of protection after 28 days was 72% in the
USA, 66% in Latin America, and 57% in South Africa. Overall, this vaccine was 85% effective
in preventing hospitalization and death across all regions, which deemed it effective [4].

Using the given raw data from the Pfizer case study, I did my own calculations to mimic
how both Pfizer and J&J got their trial results.

Vaccine Efficacy:
Risk of COVID-19 among vaccinated:

8
21720

= . 00036 = . 036%

162

Risk of COVID-19 among unvaccinated: 21728 = . 0075 = . 75%
Risk Ratio:

.00036
.0075

= . 048

Vaccine Efficacy:

(.75−.036)
.75

= . 952 = 95.2% effective

Confidence Interval of Vaccine Efficacy:
Cases (𝑋, 𝑌) = (8,162)
Participants = 43540
Efficacy = 95.2%
7

Risk Ratio: 𝑅𝑅 = . 048
1 1

95% Confidence Interval = 1 − 𝑅𝑅

(±1.96√(𝑥+𝑦))

1

1 1

I calculated the 95% Confidence Interval as follows: 1 − 𝑅𝑅

(1.96√(𝑥+𝑦))

= 1 −. 048

1

(√(8+162))

= 1 −. 048 (.70987)
= . 90238

1 − 𝑅𝑅

1 1
(−1.96√( + ))
𝑥 𝑦

= 1 −. 048

1 1
(−1.96√( +
8 162))

= 1 −. 048(−.70907)
= . 9764

Thus, the 95% Confidence Interval = (0.902,0.976)
Therefore, this is accurate because 95.2% lies within this interval.

To do these calculations accurately, I calculated the variance of the log of the risk ratio
log (𝑅𝑅), and constructed a 95% Confidence Interval based on a Poisson distribution
assumption. The Risk Ratio can be determined by a ratio of the disease rates of the vaccinated
group to the control group (unvaccinated group). This means, the smaller the rate among the
vaccinated relative to the unvaccinated, the higher the vaccine efficacy. For the Confidence
Interval, both the vaccinated group (X) and control group (Y) follow a Poisson Distribution.
Confidence Intervals are sometimes also calculated by using Binomial distribution, however for
this kind of study, the Poisson distribution allows for a more realistic interval. Since COVID-19
exposure has to be taken into account, the individuals recruited over time could possibly have
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had different exposures. This makes Binomial distribution less accurate because we cannot
assume equal distribution [5].

Overall, my calculations using the raw data from the Pfizer trial match up with the
statistics that Pfizer stated in their case study.

Based on the case studies, trials, and efficacy calculations of the Moderna, Pfizer, and
Johnson & Johnson vaccines, each vaccine was deemed effective in preventing severe COVID19 related illness. Thus, each vaccine was given FDA approval. However, the data shows that
J&J has a greater variability than both Modern and Pfizer since, by early 2021, it was the only
vaccination that had been tested against other variants [6]. The J&J vaccine was also found to
be far less effective than Moderna and Pfizer. This efficacy difference is due to the fact that the
studies were done at different times in different environments against a background of different
strains. Consequently, the J&J vaccine is hard to compare to Pfizer and Moderna. Although the
efficacy of Moderna and Pfizer is significantly higher than Johnson & Johnson, all three vaccines
have a 100% efficacy against hospitalization and death, which is the most important aspect of the
vaccine trials to gain FDA approval [7].

Although the J&J, Moderna, and Pfizer vaccine ultimately gained FDA approval for its
efficacy against severe COVID-19 illness, it is crucial to further delve into the similarities and
differences of these vaccines and analyze case studies with data similar to the results of the initial
successful trials.
9

By February 2021, the J&J vaccine could be given to people 18 and older, the Pfizer
vaccine was able to be given to people ages 16 and older, and Moderna was actively doing case
studies on administering the vaccine in people ages 12 - 17 years old. This case study was the
beginning to many other trials that would eventually allow the vaccines to be given to people
younger than 18 years old. Other than age restrictions early on in the vaccination roll-out phase,
the main difference between the Moderna, Pfizer, and J&J vaccines is that J&J is a Viral
Vectored Vaccine, whereas Pfizer and Moderna are made using mRNA. Thus, each vaccine
requires different storage procedures. Since Moderna and Pfizer are mRNA vaccines, they are
required to be stored at cold temperatures, which creates accessibility problems. However, since
J&J is a Viral Vectored Vaccine, it requires no special storage procedure, and therefore will be
able to be administered in more places than the Pfizer or Moderna vaccine.

Along with different storage procedures, each vaccine also has a different timeline of efficacy.
This timeline of efficacy is initially dictated by the fact that J&J is a single dose vaccine, whereas
Moderna and Pfizer are two-dose vaccines, as of February 2021, before third doses were
necessary and available. The intervals between doses are as follows: Moderna - 28 days; Pfizer21 days; J&J – single dose.

The common side-effects after each vaccine dose also vary between each vaccine type.
Most side-effects occur after the second dose of Moderna/Pfizer is administered, which cannot
be compared to the J&J single dose vaccine. Anaphylaxis has been another side effect for some
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people receiving Moderna or Pfizer, but there is only one case of anaphylaxis associated with the
J&J vaccine as of February 2021 [6]. Other COVID-19 vaccine related side-effects that have
been observed include injection site soreness, nausea, headache, and fever.

Shortly after the FDA approval of Moderna, J&J, and Pfizer vaccines in the United States
and across the globe, Canada gained FDA approval for a fourth vaccine created by AstraZeneca.
The AstraZeneca trial used a meningococcal vaccine rather than a placebo for the control group.
This caused some younger participants to experience reactions from both the COVID-19 vaccine
and the meningococcal vaccine. The expected side effects seem to be worse after the second dose
of Moderna and Pfizer, while they are worse after the first dose of AstraZeneca. Otherwise, the
side effects remained very similar in all four vaccines. These side effects are extremely similar to
those due to vaccines such as the shingles vaccine, but worse than the side effects from the flu
vaccine. This trial also showed that the efficacy of the AstraZeneca vaccine was much closer to
that of J&J, than to the efficacy of Moderna and Pfizer. More specifically, J&J and AstraZeneca
both had around a 60-70% efficacy, while both Moderna and Pfizer had an efficacy of ~95% [8].
An explanation of the lower efficacy in the AstraZeneca and J&J vaccines could be from a
greater number of infections from variants of concern; however, it is difficult to compare the
efficacy of these vaccines due to the differing amounts of doses needed and timing of said
dose(s). Alison Thompson, an associate professor who studies public health policy and ethics at
the University of Toronto, also pointed out that the difference in efficacy between these vaccines
might change over time and close the gap between the efficacy of these four vaccines. She said,
“As we get more data about the kind of efficacy that they have over the longer term, we may see
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those [efficacy] numbers come down significantly for the mRNA [Pfizer and Moderna]
vaccines” [8].

Some similarities amongst all four vaccines include: they seem to equally protect
different age groups, sexes, and races, when combating more severe cases and hospitalizations,
and they satisfy Health Canada’s 50% efficacy standard. However, these vaccines also have
many differences. The main difference between Moderna, Pfizer, J&J, and AstraZeneca is that
Moderna and Pfizer trick the immune system by using mRNA to provoke a response, while J&J
and AstraZeneca use adenovirus (another respiratory virus) to provoke a response from the
immune system. The storage of these vaccines is also different. Moderna and Pfizer have to be
stored in freezers, while J&J and AstraZeneca can be stored in refrigerators.

Following the approval and authorization of the Moderna and J&J vaccines for ages 18+,
and the authorization of the Pfizer vaccine for ages 16+ and Pfizer, case studies and trials were
carried out by both Moderna and Pfizer to lower the age limit of the COVID-19 vaccine. In
January of 2021, Pfizer conducted a trial with 2,200 young adults aged 12–15. Shortly after in
February of 2021, Moderna conducted a trial with 3,000 young adults aged 12–17 [8]. Since
these trials were successful and deemed the vaccine effective and safe for children ages 12 and
older, Moderna started testing their vaccine in babies and children 6 months - 11 years old in
mid-March of 2021.
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For this trial, which included 6,750 infants and children between 6 months and 11 years
old, Moderna began testing different doses on the participants. Some participants only received
one-quarter of the dose that was currently being administered to adults, while others were given
one-half the dose or an equal dose to that of an adult. Through this trial technique, Moderna was
able to determine the correct doses for infants and children. Then, Moderna followed up this trial
with a trial comparing the correct dosage for young children against a placebo injection. Stephen

Spector, a professor of pediatrics at the University of California San Diego School of
Medicine, who led a trial of the Moderna vaccine measured the efficacy of the vaccine in
young children by measuring “the levels of neutralizing antibodies, which prevent SARSCoV-2 from infecting cells” [9].

Although it is more difficult to prove that the vaccine is effective in children because
children are less likely to show COVID-19 symptoms than compared to adults, it is imperative
that young children get vaccinated to gain herd immunity. Since the age group of Unites States
citizens 18 years and younger make up about 23% of the United States population, thus making
it nearly impossible to gain herd immunity without the vaccination of this demographic.

According to the United States Centers for Disease Control and Prevention, as of March
17, 2021, 226 people under 18 died with COVID-19 in the United States, compared with more
than 417,000 deaths of people ages 65 and older and more than 517,000 deaths overall [9]. Thus,
although officials predicted that a vaccine for children may take months or even a year to
authorize, Spector, along with the chair of the Committee on Infectious Disease for the
13

American Academy of Pediatrics, Dr. Yvonne Maldonado, believe that the vaccine is crucial
for the health and safety of young children and those in contact with them. Dr. Maldonado,
who was working on the Pfizer trial for young children, said, “I - by training, I'm a vaccinologist.
And I do believe that - we know that vaccines have prevented 75% of deaths in children around
the world in the last 20 years” [10].
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Section 2
Throughout the entirety of the COVID-19 Pandemic, the Mississippi State Department of
Health has provided updated data regarding COVID-19 and the COVID-19 vaccine. By tracking
this data for a full year, I have been able to put together and analyze graphs in order to
demonstrate and prove the efficacy of the COVID-19 vaccine. The COVID-19 vaccination data
that I have tracked and graphed includes the data for Moderna, Pfizer, and J&J vaccines
combined rather than separate data for each vaccine type. Also, the term “fully vaccinated” refers
to a person who has received two doses of Moderna or Pfizer and a single dose of the J&J
vaccine and onset is 14 days after the last dose was received. Thus, individuals who have only
received one dose of Moderna or Pfizer are counted in the “unvaccinated” or “not vaccinated”
category.

Figure 1.1
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Figure 1.2

Figure 1.3
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As shown in Figure 1.1 and Figure 1.3 above, as more first and second dosages were
administered in the State of Mississippi starting in February 2021, the number of hospitalizations
due to the Alpha variant of COVID-19 began to decrease. However, in early July 2021, there is a
clear spike in COVID-19 hospitalizations despite the increasing numbers of people receiving the
COVID-19 vaccine, as seen in Figure 1.2. This spike was due to a new COVID-19 variant hitting
Mississippi, this variant being known as the Delta variant.

In late July 2021, a case study was done regarding the efficacy of the COVID-19 vaccine
against the Delta variant. This trial had a test-negative case control design which compared the
vaccination status of a symptomatic COVID-19 patient versus the vaccination status of a
symptomatic patient with a negative COVID-19 test. This method tests the difference between
the efficacy of the vaccine against Delta compared to the efficacy of the vaccine against Alpha in
patients 16 years of age and older. It should be noted that this trial considered a vaccinated
person to have received either one dose or two doses, with symptoms occurring 21 or more days
after the first dose was administered and 14 or more days after the second dose was
administered.

To differentiate the patients with the Delta variant rather than the Alpha variant, wholegenome sequencing was used. Along with sequencing, PCR testing on the spike (“S”) gene target
status was used to identify the Delta variant amongst the positive COVID-19 samples being
analyzed. The S Target was helpful in this identification because it was discovered in April 2021
that approximately 98% to 100% of the Alpha variant COVID-19 cases tested negative for the S
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Target, while 72.2% of the Delta variant COVID-19 cases tested positive for the S Target. This
result increased in May 2021 when it was discovered that 93% of the samples that were deemed
cases of the Delta variant contained a positive S Target.

The results of this trial showed that among the 19,109 sequenced sample tests that were
used in this trial, vaccination status was linked to approximately 92% of these samples. By the
end of the trial, the Alpha variant was detected in 14,837 of the samples and the Delta variant
was detected in 4272 of the samples. Thus, by analyzing these results, it was found that the
efficacy of a single dose of the vaccine was significantly lower against the Delta Variant than
against the Alpha variant. More specifically, one dose of the COVID-19 vaccine was
30.7% effective against the Delta variant with a 95% Confidence Interval of (25.2,35.7). This
can be compared to the 48.7% efficacy of one dose against the Alpha variant, with a
95% Confidence Interval of (45.5,51.7).

It is apparent that the difference between the efficacy of a single vaccine dose against the
Alpha variant and the Delta variant is fairly significant; however, the results of the efficacy of
two doses of the vaccine had a much smaller difference. The data shows that being fully
vaccinated is 93.7% effective against the Alpha variant and 88.0% effective against the Delta
variant, with 95% Confidence Intervals of (91.6,95.3) and (85.3,90.1) respectively [11].

Although the results of this case study seemed hopeful for the efficacy of the vaccine
against the Delta variant, over time as the numbers of vaccinations increased, the number of
18

severe COVID-19 cases increased as well [Fig. 1.3]. Thus, the Delta variant introduced a
problem that needed to be solved quickly and effectively. Unlike the Alpha variant, which
mainly targeted the elderly and immunocompromised, the Delta variant targeted the younger
unvaccinated population.

The third dose, or booster shot, of the vaccine was highly encouraged and available to
people 50 years of age and older by August 2021. Around this time, the Israeli Minister of
Health Nitzan Horowitz received his third dose and encouraged the Israeli citizens, along with
the rest of the world, to follow suit. He cautioned, “Now is a critical time... We’re in a race
against the pandemic” [12]. By August 2021, Israel not only had some of the world’s highest
vaccination rates with 78% of the Israeli population 12 years and older being fully vaccinated, it
also had some of the highest infection rates in the world with more than 600 new COVID-19
cases per day per every million people.

Through the course of the Pandemic, Israel was being watched closely by the rest of the
world due their early and extensive vaccination of their population. Thus, as the Delta variant
became more and more threatening, the world looked to Israel as the model. As of August 2021,
research found that people that received their vaccinations in January were 2.26 times more
likely to get a breakthrough infection than people who received the vaccine in April. This shed
some light on the situation in Israel because most of the Israeli citizens received their vaccination
in the time frame from December 2020 to February 2021. Similarly, regarding the spike in cases
in the rest of the world, the people that received their vaccinations first were the elderly and
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those with the weakest immune systems [12]. Therefore, although the Delta variant targeted the
young unvaccinated portion of the population, the vaccinated elderly and immunocompromised
portion of the population were also being affected due to the vaccine efficacy decreasing over
time.

By August 15, 2021, a total of 514 Israelis were hospitalized due to a severe case of
COVID-19. Of these people, 59% were fully vaccinated and 87% of the fully vaccinated patients
were 60 years of age or older. However, according to data from the Ministry of Health, people 60
years of age and older who have received a third dose were half as likely to be hospitalized as
their fully vaccinated peers. Due to this data and the concerning amount of severe COVID-19
cases rapidly arising in Israel, the country administered third doses of the COVID-19 vaccine to
over one million citizens by late August 2021. Luckily, out of 4500 people who got vaccination
boosters, 88% said symptoms were no worse than the other doses [12].

Ultimately, as Figure 1.3 shows, the spike of hospitalizations due to the Delta variant did
not respond to the increase of vaccinations until the third dose of the vaccine was introduced.
After the third dose was administered to more and more Mississippi residents, the spike due to
the Delta variant began to decrease and COVID-19 hospitalizations were far less frequent.
Therefore, the third dose was effective against severe illness and hospitalizations due to COVID19. This relationship between the third COVID-19 dose and severe COVID-19 hospitalizations is
demonstrated by the red X marked on Figure 1.3 [Fig. 1.3].
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Section 3
After the third dose of the vaccine helped to blunt the increasing severe COVID-19 cases
due to the Delta variant, another COVID-19 variant was introduced. Beginning in late December
2021, the Omicron variant made its way to Mississippi despite the increasing vaccination status
of the state as a whole.

Figure 2.1
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The Omicron variant was deemed less severe than the Alpha and Delta variants by many
people across the globe; however, was this really the case? An associate professor of
epidemiology at Harvard, William Hanage, and an assistant professor at Massachusetts General
Hospital and Harvard Medical School, Roby Bhattacharyya, recently published a paper in which
they stated that the perception of the Omicron virus to be “milder” was actually due to greater
level of population immunity. They hypothesized that being vaccinated against or exposed to any
other strain of COVID-19 most likely helped to reduce the severity of a possible Omicron
infection. However, they still strongly believe that unvaccinated people need to get vaccinated
and vaccinated people need to get boosted to protect themselves and others from severe COVID19 related illness [13].

A case study regarding the efficacy of the COVID-19 vaccine and booster against the
Omicron variant that used a test negative case-control design discovered that the vaccine had
limited effect against the Omicron variant. The data showed that two doses of a COVID-19
vaccine was 65.5% effective against the Omicron variant at 2-4 weeks after vaccination, however
this efficacy drops below 10% at 25 or more weeks after vaccination. However, the third dose
managed to increase the efficacy against Omicron at 2-4 weeks after vaccination to 73.9% , but
this efficacy percentage also decreased over time [14].

The Omicron variant is marked on Figure 2.1 with a red X [Fig. 2.1]. It can be seen that
the peak of Omicron is lower than that of the Delta variant. Additionally, the duration of the
Omicron spike is significantly less than that of the Delta variant as well. Thus, although the
vaccine is not nearly as effective against the Omicron variant as it was against the Alpha and
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Delta variants, the previous immunity gained through vaccination or exposure to COVID-19
helped to make Omicron a less severe variant.
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Section 4
As mentioned in Section 1, early in the COVID-19 pandemic, the vaccine had to go
through many trials before it was approved for children under the age of 18. After extensive
research, the Centers for Disease Control and Prevention slowly started to lower the age at which
someone is able to receive the vaccination(s).

Figure 3.1

As shown in Figure 3.1 above, in February 2021, the age groups containing
Mississippians 65 years of age and older were the people with the greatest vaccination rate [Fig
3.1]. This makes sense because around this time, the elderly (65+ years of age) and
immunocompromised were the main demographic that were able to get vaccinated. A few
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months later in late March of 2021, the data shows that the age group ranged for 50 to 64 years
of age surpasses the 65+ age group for vaccination status as a whole. Although the vaccination
status of the other age groups increases significantly over time, no age group increases quite as
much as the group containing people 50 - 64 years of age.

In May 2021, the age requirement to receive the vaccine was lowered to 12 years of age
and older. Thus, as Figure 3.1 demonstrates, data regarding vaccination of the age group
containing Mississippians aged 12 –15 years was introduced [Fig. 3.1].

Figure 3.2
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Beginning in November of 2021, the CDC approved the COVID-19 vaccine for children
ages 5 and older. As Figure 3.2 demonstrates, this age group has been slowly receiving the
vaccination since November of 2021, and remains the youngest age group that is approved to
receive the COVID-19 vaccine as of January 2022. Overall, each age group that is able to receive
the COVID-19 vaccine has had a steady increase in vaccinations over time [Fig. 3.2].

According to the CDC, as of January 2022, Pfizer is the only vaccine FDA approved for
individuals 17 years of age and younger. Currently, Moderna and J&J are not FDA approved to
be administered in individuals younger than 18 years of age. The CDC also encouraged
individuals 12 years of age and older to receive a third dose of the COVID-19 vaccine in order to
protect themselves and others against contracting severe COVID-19 cases [15].
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Section 5
Ultimately, the efficacy of the COVID-19 vaccine can be best proven by the risk
reduction it provided and its overall prevention of COVID-19 related deaths. Early on in the
COVID-19 pandemic, specifically the time period from December 2020 to February 2021, newly
vaccinated people were matched up in a 1:1 to unvaccinated people that had similar
characteristics and demographics. Since the unvaccinated people acted as a control group, a
study was able to be conducted on the approximate vaccine efficacy by using the Kaplan-Meier
estimator [16].

The Kaplan-Meier Method is a statistical treatment of survival times. It measures the
number of subjects who survived or were saved after an intervention over a period of time.
Subjects in the study who drop out of a case study due to uncooperativeness or death are labeled
as “censored observations” [17]. This method assumes that censored patients have the same
survival prospects as patients who continue to participate in the study. This method also assumes
that the survival probability for subjects recruited at any point in the case is the same. Lastly, this
method assumes that the event happens at the time specified. According to the U.S. National
Institutes of Health’s National Library of Medicine, “The Kaplan-Meier survival curve is defined
as the probability of surviving in a given length of time while considering time in many small
intervals” [17].

The Survival probability can be calculated as follows:
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𝑆=(

# 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑙𝑖𝑣𝑖𝑛𝑔 𝑎𝑡 𝑠𝑡𝑎𝑟𝑡 − # 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑑𝑖𝑒𝑑
)
# 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑙𝑖𝑣𝑖𝑛𝑔 𝑎𝑡 𝑠𝑡𝑎𝑟𝑡

In this case study, which used the Kaplan-Meier Method, there were 1,163,534
participants, with two groups of 596,618 people all of which being 16 years of age or older. As
previously mentioned, the vaccinated participants along with the unvaccinated control
participants that were paired up each had similar variables associated with the probability of the
vaccination and infection. The covariate balance was evaluated after matching up the vaccinated
participants and control / unvaccinated participants. A difference of 0.1 or less was considered to
be an acceptable pairing [16]. Based off of the results in Table 1, one can conclude that two
doses of the vaccine were much more effective than a single dose of the vaccine, however a
single dose of the vaccine was still much more effective than no doses of the vaccine at all
[Table 1].

These results of this case study are as follows:
COVID-19 Vaccine Efficacy
Documented Infection
Symptomatic COVID-19
Hospitalization
Severe Disease
Death

14-20 days
(After 1st dose)
46%
57%
74%
62%
72%
Table 1

7+ days
(After 2nd dose)
92%
94%
87%
92%
-

Although the efficacy of the COVID-19 vaccine against severe illness was calculated and
predicted early in the pandemic, the data is not as relevant after the different variants were
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introduced. Luckily, there are equations and formulas that allow for the risk reduction that the
vaccine provides to be calculated and updated over the course of the pandemic.

According to the CDC, the age-standardized Incidence Rate Ratios (“IRRs”) can be
successfully calculated by finding the incidence among people who are not fully vaccinated
and dividing that by the incidence among fully vaccinated persons. In order to take account
of weekly rate variations, 95% Confidence Intervals are calculated for the IRRs. To help
demonstrate changes in IRRs, Vaccine Effectiveness (“VE”) is estimated as:
𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑖𝑛 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑

(1 − [𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑖𝑛 𝑢𝑛𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑒𝑑 ]) [18].

Similarly, the expected percentage of vaccinated People Among Cases (“PVC”) was
calculated with the following formula:

𝑃𝑉𝐶 =

[𝑃𝑃𝑉 − (𝑃𝑃𝑉 ∗ 𝑉𝐸)]
[1 − (𝑃𝑃𝑉 ∗ 𝑉𝐸)]

*PPV is the proportion of the population vaccinated.
*PVC was calculated using VE estimates of 80%, 90%, and 95%.
By using these calculations, the CDC found that during the time period from April 4,
2021, to July 17, 2021, the IRR decreased by mid-June. They were able to do these calculations
based on the data of unvaccinated and fully vaccinated people during this time period. The
unvaccinated group consisted of 569,142 (92%) COVID-19 cases, 34,972 (92%)
hospitalizations, and 6,132 (91%) COVID-19-associated deaths. On the other hand, the
vaccinated group consisted of 46,312 (8%) COVID-19 cases, 2,976 (8%) hospitalizations, and
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616 (9%) deaths. However, by June 20, 2021, the vaccinated group consisted of 18% COVID-19

cases, 14% hospitalizations, and 16% deaths.

From this data, the CDC discovered that the IRRs for cases of unvaccinated people
versus cases of vaccinated people decreased to 4.6 in late June from a previous 11.1 in early
April. The IRRs also decreased over the same time period for hospitalizations and deaths. These
IRRs decreased to 10.4 from 13.3 and to 11.3 from 16.6, respectively. From these IRRs, the VE
was able to be calculated, and a decrease over time was also discovered in these calculations.
The VE against positive cases or infections due to COVID-19 changed from 91% to 78% from
April to July, respectively. During this same time period, the VE against hospitalization
decreased slightly from 92% to 90% , while the VE against death decreased from 94% to
91% [18].

These results provide both the risk reduction and vaccine efficacy against three different
levels of COVID-19 severity. It demonstrated that, although the efficacy and risk reduction
decreased over time, the vaccine still provided sufficient protection against all degrees of
COVID-19 severity. Since the COVID-19 vaccine prevents and protects people against severe
COVID-19 related illness, such as death and hospitalization, it makes sense that these two
categories had the highest efficacy and risk reduction compared to the category containing
positive cases.
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Along with these calculations, the raw COVID-19 data provided to me by the Mississippi
State Epidemiologist, Dr. Paul Byers, along with the Mississippi Office of Epidemiology
(including Theresa Kittle, Davis Trewolla, and Britney Rust) over the course of the pandemic
also proves the overall efficacy of the COVID-19 vaccine against many different levels of
COVID-19 severity. By dividing the overall COVID-19 related deaths in Mississippi into
unvaccinated and vaccinated groups, it became clear that the vaccine was, in fact, effective
against the most severe COVID-19 cases, which may result in death.

Figure 4.1
By analyzing the raw data, I was able to create a graph that has three categories: fully
vaccinated deaths, unvaccinated deaths, and total combined deaths. As Figure 4.1 clearly
demonstrates, those who have received two doses of the COVID-19 vaccine were far less likely
to succumb to COVID-19 related illness when compared to those who were unvaccinated. As
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expected, this data followed the timeline of the vaccine rollout discussed in previous sections.
After people were able to receive the vaccination in Mississippi, the number of vaccinated deaths
remained significantly lower than unvaccinated deaths throughout the remaining duration of the
pandemic. This is demonstrated by the blue line in comparison to the orange line on Figure 4.1
[Fig. 4.1].

The death by vaccine status data also allowed me to manually calculate the approximate
COVID-19 vaccine efficacy (VE) against death for each month, as well as an overall efficacy. I
did this by using the Vaccine Efficacy formula (previously mentioned in this section) along with
the data from Table 2.
COVID-19 Deaths by Vaccination Status (MS)

COURTESY: Mississippi State Department of Health
Table 2
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The calculations are as follows:
April 2021: 752,538 fully vaccinated individuals
0.2528 vaccinated, 0.7471 unvaccinated
120

𝑉𝐸 =

1

(0.7471 −0.2528 )
120

(0.7471 )

= 0.9753
= 97.53%

Thus, the vaccine efficacy against death for April 2021 was 97.53%. I then did this same
calculation for every month following until February 2022. The results are show in Table 3.

Month- Year
April- 2021
May- 2021
June- 2021
July- 2021
August- 2021
September- 2021
October- 2021
November- 2021
December- 2021
January- 2022
February- 2022

COVID-19 Vaccine Efficacy against Death
97.53%
68.91%
67.58%
58.84%
73.07%
77.21%
74.24%
68.25%
61.62%
38.47%
44.38%
Table 3

I then added the data for each month together to calculate the overall COVID-19 vaccine
efficacy against death in Mississippi. The results are as follows:
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Overall VE: 1488845 fully vaccinated individuals
0.5003 vaccinated, 0.4997 unvaccinated
10960

𝑉𝐸 =

1049

(0.4997 −0.5003 )
10960

(0.4997 )

= 0.90198
≈ 90.2%

Therefore, the overall COVID-19 vaccine efficacy against death in Mississippi is
approximately 90.2%. Thus, deeming the COVID-19 vaccine highly effective in preventing
death due to COVID-19- related illness.
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Section 6
As the pandemic continued to take over the world for months on end, many
epidemiologists and researchers across the globe noticed a familiarity of the pattern that COVID19 and its variants were presenting. This pattern led a professor at the Department of
Epidemiology and Biostatistics at Michigan State University to perform a study which compared
the trendlines of severe illness due to the COVID-19 pandemic and the 1918 Spanish Influenza
pandemic. This professor, Siddharth Chandra, who is also an economics professor, created a
graph that depicts the overall pattern of deaths due to the 1918 Spanish Influenza pandemic in
Michigan over the entirety of the pandemic from 1918 to 1920 [19].
Spanish 1918 Influenza Deaths per Month in Michigan

COURTESY: Siddharth Chandra

Figure 5.1
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Figure 5.2

With Professor Chandra’s graph in mind, I recreated a similar graph using the data of
monthly COVID-19 related deaths in Mississippi from 2020 to 2022. As demonstrated in both
Figure 5.1 and Figure 5.2, there were four major waves or spikes that are marked on each graph
[Fig. 5.1], [Fig. 5.2]. This side-by-side comparison clearly demonstrates the similar trendlines
that these two pandemics provided over the course of two years. However, in 1918, there was no
vaccine. Thus, epidemiologists and scientists today can analyze the 1918 pandemic and use its
data as somewhat of a control group to provide some clues as to what might occur in the current
or future pandemics.
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In a study conducted comparing the COVID-19 and the 1918 Spanish Influenza
Pandemics in the United Kingdom, it was confirmed that the two pandemics have extremely
similar waves of infection over the course of the pandemic. The two pandemics share some
similarities, such as the basic reproductive number (𝑅0 ), which is the average number of infected
contacts per infected person according to the textbook Virus as Populations [20]. The (𝑅0 ) of
both the 1918 Pandemic and the current COVID-19 pandemic ranges from 2 to 4. Both
pandemics also share the characteristics of high fatality rates and rapid spread.

This study used a comparable dispersion parameter (𝑘), which “controls the variance in
distribution of the number of secondary cases caused by a typical primary case” [21]. In this
study, it was found that the Spanish 1918 Influenza A/H1N1 had a 𝑘 = 0.94 while the COVID-19
has an approximate 𝑘 = 0.80 [21]. Since a small k-value implies a large contribution by superspreaders (events with many people) to the total number of infections, both the similar and large
k-values represent that both the COVID-19 and 1918 Spanish Influenza infections are
challenging to control, and easily sustained within a population. Thus, it is important to focus
upon individual COVID-19 cases rather than super-spreader events [22]. The COVID-19 vaccine
proved to be beneficial because it focused upon the individual and those around them. Because
vaccine technology was not advanced in 1918, the data provided by the 1918 Spanish Influenza
pandemic could be useful in predicting and improving the outcome of future pandemics.

In another dispersion-based study conducted regarding the risk reduction provided to an
entire family by only a few vaccinated family members, it was discovered that the unvaccinated
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family members were at a lower risk due to their vaccinated relatives. These results were found
in Sweden (mid-2021) by matching 1:1 a person with immunity, from either the COVID-19
vaccine or a previous COVID-19 infection, to a person without COVID-19 immunity in families
containing 2 to 5 members. In this study, there were a total of 1789728 people from 814806
families. The risk reduction of contracting a severe COVID-19-related illness for a non-immune
family containing a single immune member was 45% to 61% . This risk reduction increased as
the number of family members with immunity also increased. In families contain two immune
family members, the risk reduction was 75% to 86% , while families containing 3 or 4 family
members had a risk reduction that ranged from 91% to 97% [23].

Applying past lessons to the present, not only can the COVID-19 vaccine provide
protection to an individual, but it can also help protect an individual’s loved ones. Ultimately, as
the data reveals, getting vaccinated is a vital strategy to decrease and hopefully eliminate
COVID-19. Therefore, when deciding whether to receive the vaccine, think of the people that
would have benefited from a vaccine during the 1918 Spanish Influenza. The COVID-19 vaccine
is beneficial for more than just the individual that receives it, it is also beneficial for those in
proximity.
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Conclusion
The COVID-19 pandemic has clearly been detrimental not only in Mississippi, but also in
the entire world. By doing an in-depth analysis of the data provided by the Mississippi State
Health Department (approximately two years), the overall efficacy of the COVID-19 vaccines
has been proven. Despite the politicization of COVID-19 and its vaccine, the efficacy data
remains strong. Thus, by following the wise words of John Adams and eliminating the politics
surrounding the vaccine, the facts are clear that the COVID-19 vaccine is effective in preventing
severe COVID-19-related illnesses, hospitalizations, and deaths.
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